A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Completed · Phase 1 · NCT03236857
Conditions: Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Non-Hodgkin's Lymphoma, Neuroblastoma
At a glance
- Research payments reported, 2025
- $14,504
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 143
About the trial
- Sponsor
- AbbVie (with Roche-Genentech)
- Tested
- chemotherapy (drug), venetoclax (drug)
- Dates
- Started 2017-11-08; completion 2023-04-19
- Results posted
- Not yet
An open-label, global, multi-center study to evaluate the safety and pharmacokinetics of venetoclax monotherapy, to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary efficacy of venetoclax in pediatric and young adult participants with relapsed or refractory malignancies.
From ClinicalTrials.gov, last updated 2023-05-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $14,504 in research payments for this study in 2025 (1 payments).
Products named: Venclexta
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- St Jude S Children S Research Hospital $14,504
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.